File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: H3K27me3 protein is a promising predictive biomarker of patients' survival and chemoradioresistance in human nasopharyngeal carcinoma

TitleH3K27me3 protein is a promising predictive biomarker of patients' survival and chemoradioresistance in human nasopharyngeal carcinoma
Authors
Issue Date2011
PublisherThe Feinstein Institute for Medical Research. The Journal's web site is located at http://www.molmed.org
Citation
Molecular Medicine, 2011, v. 17 n. 11, p. 1137-1145 How to Cite?
AbstractTrimethylation of lysine 27 on histone H3 (H3K27me3) is an epigenetic change which plays a critical role in tumor development and/or progression. However, the molecular status of H3K27me3 and its clinicopathologic/prognostic significance in nasopharyngeal carcinoma (NPC) have not been elucidated. In this study, the methods of Western blotting and immunohistochemistry (IHC) were utilized to examine the expression of H3K27me3 protein in NPC tissues and nonneoplastic nasopharyngeal epithelial tissues. Receiver operating characteristic (ROC) curve analysis was used to determine the cutpoint for H3K27me3 high expression. High expression of H3K27me3 could be observed in 127/209 (60.8%) of NPCs and in 8/50 (16.0%) normal nasopharyngeal epithelial tissues (P < 0.001). Further correlation analysis demonstrated that high expression of H3K27me3 was positively associated with tumor later T classification, tumor metastasis, advanced clinical stage and chemoradioresistance (P < 0.05). Moreover, high expression of H3K27me3 was closely associated with NPC patient shortened survival time as evidenced by univariate and multivariate analysis (P < 0.05). Consequently, a new clinicopathologic prognostic model with three poor prognostic factors (H3K27me3 expression, distant metastasis and treatment regimen) was constructed. The model could stratify risk significantly (low, intermediate and high) for overall survival and progression-free survival (P < 0.0001). These findings provide evidence that H3K27me3 expression, as examined by IHC, has the potential to be used as an immunomarker to predict NPC chemoradiotherapy response and patient prognosis. The combined clinicopathologic prognostic model may become a useful tool for identifying NPC patients with different clinical outcomes. © 2011 The Feinstein Institute for Medical Research.
Persistent Identifierhttp://hdl.handle.net/10722/150844
ISSN
2014 Impact Factor: 4.508
ISI Accession Number ID
Funding AgencyGrant Number
973 Project of China2010CB912802
2010CB529401
Foundation of Guangzhou Science and Technology Bureau, China2005Z1-E0131
Funding Information:

This work was supported by the 973 Project of China (2010CB912802 and 2010CB529401) and the Foundation of Guangzhou Science and Technology Bureau, China (2005Z1-E0131).

References

 

DC FieldValueLanguage
dc.contributor.authorCai, MYen_US
dc.contributor.authorTong, ZTen_US
dc.contributor.authorZhu, Wen_US
dc.contributor.authorWen, ZZen_US
dc.contributor.authorRao, HLen_US
dc.contributor.authorKong, LLen_US
dc.contributor.authorGuan, XYen_US
dc.contributor.authorKung, HFen_US
dc.contributor.authorZeng, YXen_US
dc.contributor.authorXie, Den_US
dc.date.accessioned2012-06-26T06:12:08Z-
dc.date.available2012-06-26T06:12:08Z-
dc.date.issued2011en_US
dc.identifier.citationMolecular Medicine, 2011, v. 17 n. 11, p. 1137-1145en_US
dc.identifier.issn1076-1551en_US
dc.identifier.urihttp://hdl.handle.net/10722/150844-
dc.description.abstractTrimethylation of lysine 27 on histone H3 (H3K27me3) is an epigenetic change which plays a critical role in tumor development and/or progression. However, the molecular status of H3K27me3 and its clinicopathologic/prognostic significance in nasopharyngeal carcinoma (NPC) have not been elucidated. In this study, the methods of Western blotting and immunohistochemistry (IHC) were utilized to examine the expression of H3K27me3 protein in NPC tissues and nonneoplastic nasopharyngeal epithelial tissues. Receiver operating characteristic (ROC) curve analysis was used to determine the cutpoint for H3K27me3 high expression. High expression of H3K27me3 could be observed in 127/209 (60.8%) of NPCs and in 8/50 (16.0%) normal nasopharyngeal epithelial tissues (P < 0.001). Further correlation analysis demonstrated that high expression of H3K27me3 was positively associated with tumor later T classification, tumor metastasis, advanced clinical stage and chemoradioresistance (P < 0.05). Moreover, high expression of H3K27me3 was closely associated with NPC patient shortened survival time as evidenced by univariate and multivariate analysis (P < 0.05). Consequently, a new clinicopathologic prognostic model with three poor prognostic factors (H3K27me3 expression, distant metastasis and treatment regimen) was constructed. The model could stratify risk significantly (low, intermediate and high) for overall survival and progression-free survival (P < 0.0001). These findings provide evidence that H3K27me3 expression, as examined by IHC, has the potential to be used as an immunomarker to predict NPC chemoradiotherapy response and patient prognosis. The combined clinicopathologic prognostic model may become a useful tool for identifying NPC patients with different clinical outcomes. © 2011 The Feinstein Institute for Medical Research.en_US
dc.languageengen_US
dc.publisherThe Feinstein Institute for Medical Research. The Journal's web site is located at http://www.molmed.orgen_US
dc.relation.ispartofMolecular Medicineen_US
dc.titleH3K27me3 protein is a promising predictive biomarker of patients' survival and chemoradioresistance in human nasopharyngeal carcinomaen_US
dc.typeArticleen_US
dc.identifier.emailGuan, XY:xyguan@hkucc.hku.hken_US
dc.identifier.authorityGuan, XY=rp00454en_US
dc.description.naturelink_to_OA_fulltexten_US
dc.identifier.doi10.2119/molmed.2011.00054en_US
dc.identifier.pmid21738951-
dc.identifier.scopuseid_2-s2.0-82855172243en_US
dc.identifier.hkuros203483-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-82855172243&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume17en_US
dc.identifier.issue11en_US
dc.identifier.spage1137en_US
dc.identifier.epage1145en_US
dc.identifier.isiWOS:000297958800004-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridCai, MY=39461062300en_US
dc.identifier.scopusauthoridTong, ZT=36747652800en_US
dc.identifier.scopusauthoridZhu, W=25635029800en_US
dc.identifier.scopusauthoridWen, ZZ=37063967200en_US
dc.identifier.scopusauthoridRao, HL=35277843000en_US
dc.identifier.scopusauthoridKong, LL=54796628200en_US
dc.identifier.scopusauthoridGuan, XY=7201463221en_US
dc.identifier.scopusauthoridKung, HF=7402514190en_US
dc.identifier.scopusauthoridZeng, YX=7402981579en_US
dc.identifier.scopusauthoridXie, D=35070710200en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats